Shield Therapeutics PLC (STXS)

London
40.50
-1.50(-3.57%)
  • Volume:
    432,256
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    42.00 - 42.00

STXS Overview

Prev. Close
42
Day's Range
42-42
Revenue
10.87M
Open
42.5
52 wk Range
31-148.98
EPS
-0.08
Volume
432,256
Market Cap
87.43M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
607,350
P/E Ratio
-
Beta
1.82
1-Year Change
-70.55%
Shares Outstanding
215,874,000
Next Earnings Date
10 May 2022
What is your sentiment on Shield Therapeutics PLC?
or
Market is currently closed. Voting is open during market hours.

Shield Therapeutics PLC News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellSellStrong SellStrong Sell
Technical IndicatorsBuySellStrong SellSellStrong Sell
SummaryNeutralSellStrong SellStrong SellStrong Sell

Shield Therapeutics PLC Company Profile

Shield Therapeutics PLC Company Profile

Employees
16

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Read More
  • This stock is worth over 100p
    0
    • 53.20p I’m in
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.